Advertisement
UK markets open in 7 hours 22 minutes

  • NIKKEI 225

    38,471.20
    -761.60 (-1.94%)
     

  • HANG SENG

    16,248.97
    -351.49 (-2.12%)
     

  • CRUDE OIL

    85.35
    -0.01 (-0.01%)
     

  • GOLD FUTURES

    2,399.80
    -8.00 (-0.33%)
     

  • DOW

    37,798.97
    +63.86 (+0.17%)
     

  • Bitcoin GBP

    51,298.42
    +393.24 (+0.77%)
     

  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     

  • NASDAQ Composite

    15,865.25
    -19.77 (-0.12%)
     

  • UK FTSE All Share

    4,260.41
    -78.49 (-1.81%)
     
Money:

How to avoid tax creep in retirement

The state pension went up 8.5% in April, but frozen thresholds mean pensioners will be paying more tax

Wall Street Is Still Positive on Nektar’s Immuno-Oncology Drug

Sarah Collins
Updated
Wall Street Is Still Positive on Nektar’s Immuno-Oncology Drug

Does Nektar's Stock Price Correction Signal a Good Opportunity? Nektar Therapeutics reported its biggest fall of ~42% on June 4 after the company reported preliminary results for its phase one and phase two trials for the company’s IO (immuno-oncology) candidate, NKTR-214, which was being evaluated in combination with Bristol Myers Squibb’s (BMY) Opdivo for the treatment of patients suffering from stage-IV metastatic melanoma, renal cell carcinoma, and urothelial cancers. BMY stock fell ~3% on the day.

Continue reading